STK11 and non-small cell lung carcinoma: Furthermore, a clinical trial [150] examining the combined use with the PD-1 immune checkpoint inhibitor carrilizumab and apatinib among individuals with advanced NSCLC who already received treatment with chemotherapy demonstrated a noteworthy clinical improvement for patients harboring STK11/KEAP1 mutations (The wild type, ORR is 28.1% and one-year survival is 53.1%; The mutation, ORR is 42.9% and one-year survival is 85.1%).